P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

Article 32

seehersquirt xndx

Date: 12 Dec 2007
Time: 14:40:07

Comments

http://www.seehersquirt.com/?wm_login=topis http://www.sexillustrated.com/?wm_login=topis http://www.teenybopperclub.com/?wm_login=topis http://www.teenybopperclub.com/tour2/?wm_login=topis http://www.thebigswallow.com/?wm_login=topis http://www.threesomes.com/?wm_login=topis http://www.threesomes.com/cheaptrial/?wm_login=topis http://www.milfhunter.com/?id=chikenn

Date: 27 Jun 2001
Time: 14:39:14

Comments

Alliance Pharmaceutical Corp. (ALLP) acquired an ownership position in Metracor Technologies, Inc. (formerly Via Medical Corporation), a San Diego-based medical device company.

Alliance had been collaborating with Metracor on the development of RODA® (Real-Time Oxygen Dynamics Analysis), a cardiovascular and oxygenation monitoring device for which a 510(k) marketing application was recently submitted to the Food and Drug Administration (FDA).

Metracor will be responsible for the sales and marketing of its products, including the further development and marketing of RODA. In addition to Alliance and other parties, the principal owners of Metracor are three leading venture capital firms - Galen Partners, Bank of America Venture Partners, and Enterprise Partners.

In conjunction with this transaction, existing investors will purchase $6 million of Metracor stock, bringing the amount of venture capital investment to more than $36 million.

In exchange for the payment of $500,000 in cash and the transfer of its RODA technology to Metracor, Alliance will receive an approximately 5% ownership interest in Metracor and an option to increase its ownership to approximately 35% of Metracor by payment of $14.1 million or the issuance of 1.97 million shares of Alliance common stock, at Alliance's discretion, at any time prior to December 2002.

Alliance also has an option to acquire an additional 10% of the company in exchange for either 666,000 shares of Alliance common stock or $4.7 million during this period. Alliance may be required to exercise these options under certain circumstances.

"As an outgrowth of the oxygen delivery expertise gained from our work with OxygentTM, Alliance developed software technology which, in combination with Metracor's sensor technology, serve as the foundation for RODA," said Duane J. Roth, Chairman and CEO of Alliance. "We expect that RODA will be on the market next year, and we believe that this transaction allows Alliance to participate in the enhanced valuation of Metracor as RODA is commercialized.

"Metracor will conduct the further product development efforts for RODA with the concurrent financing provided by our strong venture partners," Roth noted. "We are excited about the potential for RODA to address the needs of patient monitoring and management, particularly patients undergoing complex surgeries."

ALLIANCE

Alliance Pharmaceutical Corp. is developing therapeutic and diagnostic products based on its perfluorochemical and surfactant technologies. The Company's products are intended primarily for use during acute care situations, including surgical, cardiology, and respiratory applications. Alliance is developing Oxygent (perflubron emulsion), an intravascular oxygen carrier, in conjunction with Baxter Healthcare Corporation in the United States, Canada, and Europe. ImavistTM, an ultrasound contrast agent being developed with Schering AG, Germany, was the subject of a New Drug Application (NDA) submitted to the FDA in October 1999. In August 2000, Alliance announced that FDA had completed its review of the NDA for Imavist and found it to be approvable, upon satisfactory response to certain issues identified in the review process. LiquiVentR, a liquid perfluorochemical, is being developed for respiratory therapy applications. Additional information about the Company is available on Alliance's web site at http://www.allp.com.

DISCLAIMER

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein, including the availability of funding for development, the uncertainties associated with the conduct of preclinical or clinical studies and the timing or ability to investigate scientific data. Metracor is also subject to risks and uncertainties associated with the development of its products. The success of Metracor and Alliance's investment in Metracor may differ from Alliance's expectations. Alliance refers you to cautionary information contained in documents the Company files with the Securities and Exchange Commission from time to time, including the last Form 10-K and Form 10-Q, and those risk factors set forth in the most recent registration statement on Form S-3 (File No. 333-47032) and Form S-4 (File No. 333-49676). Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

--------------------------------------------------------------------------------

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName